Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 113

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 113
---
 a variety
of finance and operational roles including Chief Financial Officer of Amgen's Intercontinental Region from 2013 to 2018 and as its Head
of International FP&A and Interim International Chief Financial Officer from 2009 to 2013. Mr. Farag holds a BA from the University
of California, Santa Barbara.

Mr. Farag’s qualifications to serve on
our Board of Directors are primarily based on his experience as a biotech and global finance executive with a track record of scaling
companies through transformational growth.

Mr. Sigmund Rogich has served as a director
of the Company since 2020. He is the CEO and President of The Rogich Communications Group and serves on the Board of Keep Memory Alive,
a philanthropic organization which raises awareness about brain disorders and Alzheimer’s disease. Keep Memory Alive funds clinical
trials to advance new treatments for patients with Alzheimer’s, Huntington’s and Parkinson’s disease, as well as multiple
sclerosis. Mr. Rogich was formerly the U.S. Ambassador to Iceland. He has served as a senior consultant to Presidents Ronald Reagan and
George H.W. Bush. Mr. Rogich serves on multiple boards of directors for charitable causes.

Mr. Rogich’s qualifications to serve on
our Board of Directors are based on his experience in the Communications sector and philanthropic organization raising awareness about
brain disorders. His experience in service as a senior consultant to candidates of the highest office.

Mr. Michael Sherman has served as a director
of the Company since 2017. He retired from his position as a Managing Director at Barclays Plc in 2018, where he had worked since 2008.
Previously he was a Managing Director at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant
experience in healthcare finance, most recently assisting on a $450 million convertible transaction for Neurocrine Biosciences. He has
worked on successful financial transactions for Teva Pharmaceutical Industries, Amgen Inc., Cubist Pharmaceuticals, Merck & Co.,
and Cardinal Health, among other companies. After graduating from the University of Pennsylvania, Michael Sherman received his JD, cum
laude, from the Harvard Law School.

Mr. Sherman’s qualifications to serve on
our Board of Directors are primarily based on his decades of finance industry experience and investment banking. Mr. Sherman has significant
experience in healthcare finance including having worked on successful financial transactions for several pharmaceutical and healthcare
focused companies.

Role and Composition of